Representative Transactions

A central aspect of Matt’s practice is representing private and public companies through multiple rounds of funding and other significant transactions. In the past five years, Matt has handled more than 125 private financings, including seed, venture and other institutional rounds, accounting for over $2.5 billion in capital raised. Representative recent and ongoing engagements include:

• AnaptysBio, an antibody drug development company, in its $40M mezzanine private financing round, and its 2017 IPO and subsequent follow-on offerings totaling over $500M
• Apeel Sciences, a developer of plant-based coatings to preserve fresh produce and reduce food waste, in its $70M Series C financing and $250M Series D financing
• Arcutis Biotherapeutics, a developer of medical dermatology drugs, in connection with company formation, multiple rounds of financing including $95M Series C cross-over financing and 2020 IPO
• Calico, a research and development company focused on the biology of aging, in its initial formation and separation from Google (now Alphabet) and its $2.5B strategic collaboration with Abbvie
• Castlight Health, an enterprise software and healthcare navigation company, in multiple rounds of private financing, its 2014 IPO and its $135M acquisition of Jiff
• Devoted Health, a next-generation all-in-one health care company, in multiple transactions including its $1.15 billion Series D financing
• DICE Therapeutics, a novel drug discovery platform company, in its $204M initial public offering and in its conversion to a limited liability company, multiple rounds of private financing and its strategic collaboration agreements with Sanofi and Genentech
• GRAIL, a cancer diagnostics company focused on early detection, in its spin-out from Illumina, $100M Series A financing and blockbuster $1B Series B financing
  
• PassageBio, a gene therapy drug development company, in connection with company formation and negotiation of foundational license agreement with Penn, $115M Series A financing and $110M Series B financing

Matt also advises clients on pivotal transactions, including M&A transactions, IPOs and strategic collaborations. Representative recent examples include:

• Aeglea Bio, an enzyme therapeutics drug development company, in its corporate restructuring, mezzanine round of financing and its 2016 IPO
• Channel Medsystems, a medical device technology company, in its agreement to be acquired by Boston Scientific
• Denali Therapeutics, a drug development company focused on neurodegenerative diseases, in its collaboration and option agreement with F-star, and subsequent $450M acquisition of an F-star affiliated entity pursuant to exercise of the option
• Interpreta, a healthcare and genomic information analytics company, in its acquisition by Centene Corporation
• Loxo Oncology, a drug development company focused on targeted cancer therapeutics, in its mezzanine financing round and its 2015 IPO
• Sutro Biopharma, a protein therapeutics drug development company, in connection with a strategic collaboration and acquisition option agreement with Celgene
• The County of Santa Clara in connection with a pro bono engagement to launch California’s first “pay for success” project, which deployed an innovative funding and care delivery model to address chronic homelessness in Santa Clara County

Matt also frequently negotiates licenses on behalf of clients from leading universities, including Stanford University, the University of California, San Francisco and the University of California, Berkeley.

Representative Clients

• AnaptysBio
• Apeel Sciences
• BioAge Labs
• Calico
• CareSignal
• Castlight Health
• Channel Medsystems
• Devoted Health
• Dice Therapeutics
• Earli
• Federation Bio
• G2VP
• GRAIL
• Kleiner Perkins Caufield & Byers
• Lemonaid Health
• Lyra Health
• Matrixx Software
• Maze Therapeutics
• Passage Bio
• Socrates.ai
• Sonoma Biosciences
• Sutro Biopharma
• Virgin America